In an effort to lower the price of prescription drugs, the Inflation Reduction Act of 2022 established the Medicare Drug Price Negotiation Program to negotiate maximum fair prices (MFPs) for certain high-expenditure single source drugs and biologics. Richard Frank and Gerard Anderson recently commented on draft guidance by the Centers for Medicare and Medicaid Services (CMS) on the Medicare Drug Price Negotiation Program. The draft guidance specifically seeks input regarding the implementation of the Negotiation Program for initial price applicability year 2027 and manufacturer effectuation of the MFP in 2026 and 2027.

Anderson, G. & Frank, R., 2024. Comments on the Medicare Drug Price Negotiation Program, Brookings Institution. United States of America. Retrieved from https://coilink.org/20.500.12592/2uh7mpv on 29 Aug 2024. COI: 20.500.12592/2uh7mpv.